Ontuxizumab Biosimilar - Research Grade

Human

CD248

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q9HCU0

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of ontuxizumab, built around the CD248 (endosialin/TEM-1) target and supplied for research use only. It is a humanized IgG1-kappa molecule that reproduces the target specificity of the originator antibody, allowing laboratories to study CD248 engagement without the cost or access limits of the clinical drug. Because it is antigen-matched to a well-characterized anti-CD248 antibody, it is well suited as a benchmarking reference or positive/isotype-context control in binding, competition, and neutralization assays, and as a tool for antibody-dependent cellular cytotoxicity or antibody-drug-conjugate development workflows where a defined anti-CD248 binder is needed. It is offered as a low-endotoxin, research-grade preparation (typically <1 EU/mg, with ultra-low <0.5 EU/mg options), available in bulk milligram-to-gram quantities for in-vitro assays and preclinical model work. It is explicitly not the clinical therapeutic and is not intended for human or veterinary use; it is a laboratory reagent for method development, target-validation, and comparative studies. No clone designation is implied. CD248, also known as endosialin or tumor endothelial marker 1 (TEM-1), is a type I transmembrane glycoprotein of the C-type lectin-like receptor family, encoded by the CD248 gene (UniProt Q9HCU0). Its extracellular region contains a C-type lectin-like domain, a Sushi/complement-control-protein module, and EGF-like repeats. Expression is largely restricted in normal adult tissue but is upregulated on tumor-associated stromal cells, pericytes, and activated fibroblasts within the tumor microenvironment, as well as during development and tissue remodeling. CD248 contributes to stromal-cell function, pericyte behavior, angiogenesis, extracellular-matrix interactions, and tumor growth and invasion, and has been linked to platelet-derived growth factor signaling. Its restricted, stroma- and neovasculature-associated expression makes CD248 an attractive marker and target for studies of tumor vasculature and mesenchymal biology.

CD164L1, TEM1, CD248 molecule

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Ontuxizumab biosimilar available in bulk or gram quantities?

A: Yes — the Ontuxizumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Ontuxizumab suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ontuxizumab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Ontuxizumab that binds CD248; for research use only (RUO).